Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
35 results about "Cucurbitacin B" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Cucurbitacin lipsome preparation method and formulation
InactiveCN1504191AHigh encapsulation efficiencyOrganic active ingredientsDigestive systemCucurbitacin BMedicine
The invention relates to a cucurbitacin liposome composition and its preparation, which has rather high encapsulation efficiency, and can be administered through vein, muscle, oral and nasal. The constituent percentage by weight of the composition are, cucurbitacin BE or cucurbitacin B 0.001-0.1%, phospholipids 0.1-10%, cholesterin 0-5%, the phospholipids can be lecithin, di-stearoyl phosphatidyl choline, di- palmityl phosphatidyl choline, di-oleoyl phosphatidyl choline, di- palmityl phosphatidyl ethanolamine, di-stearoyl phosphatidylglycerol. The preparation according to the invention can be prepared in the form of injection, oral liquid, syrup, drop and nasal spray
Owner:SHENYANG PHARMA UNIVERSITY
Standardized Extract And Its Use In The Manufacture Of A Medicament
The present invention refers to a medicament which activates gastrointestinal movement. The medicament consists essentially of Cucurbitacin D and one or more substances form the group including Cucurbitacin A, Cucurbitacin B, Cucurbitacin E, Isocucurbitacin B and Isocucurbitacin D. The medicament is made from an extract obtained from Muskmelon Base, the fruit stem of Cucumis melo L. The medicament can promote enterokinesia in both normal animals and in animal models where gastrointestinal movement is inhibited. It has also been demonstrated to activate the movements of the stomach, small and large intestines. The extract may be used alone or in combination with the other botanical ingredients or chemical substances to form the pharmaceutical preparation.
Owner:BOTANIC CENTURY BEIJING
Cucurbitacin b and uses thereof
InactiveUS20080234244A1Enhance and improve therapeutic effect（s） of therapyReduce and ameliorate severityOrganic active ingredientsAntineoplastic agentsCucurbitacin BDisease
The present invention relates to uses of cucurbitacins and compositions comprising cucurbitacin B. The present invention also relates to methods for preventing or treating various diseases and disorders by administering to a subject in need thereof cucurbitacin B. The invention also encompass methods of developing a therapeutic that comprises a cucurbitacin using the signaling molecules in the Ras-Raf-Mek-Elk-STAT3 pathway.
Owner:ULTRA BIOTECH
Method for extracting and separating cucurbitacin B
The invention discloses a method for extracting and separating cucurbitacin B, which comprises the following steps: firstly, melon pedicels as a raw material are crushed and are refluxed and extracted by ethanol diacolation or ethanol, an extracting solution is extracted by ethyl acetate more than three times after being concentrated, and the ethyl acetate is recovered to obtain a total cucurbitacin extract; secondly, the total cucurbitacin extract is taken to be dissolved in a 25 to 45 percent of ethanol water solution, and the hydrolysis reaction is carried out in the presence of acetic acid; the pH value is adjusted to be neutral after full reaction, and the extract is concentrated to dry; and then the obtained extract is treated by purification so as to obtain a cucurbitacin B product with more than 60 percent of cucurbitacin B content, and the concentration of the acetic acid is 0.1 to 0.3 mol / L. Compared with the prior art for extracting and separating cucurbitacin B, the invention has the following advantages: the analogue (such as cucurbitacin B glucoside) of the cucurbitacin B is converted into the cucurbitacin B by the structural transformation in the process of extraction, so that the extraction rate of the cucurbitacin B is improved, the production process is simple, and the operation is simple.
Owner:ZHEJIANG UNIV OF TECH
Novel medical use of cucurbitacin
The invention belongs to the technical field of medicine and discloses novel application of Cucurbitacins, namely novel application of Cucurbitacin B, Cucurbitacin B substances, Cucurbitacin BE and a pharmaceutical composition thereof in a medicine for treating ovarian cancer and improving the quantity of leukocytes of radiotherapy patients. The Cucurbitacin can also be a cucurbitacin B monomer, an isocucurbitacin B monomer, a dihydrocucurbitacin B monomer, a cucurbitacin I monomer, and a cucurbitacin O monomer. The Cucurbitacins or pharmaceutical compositions thereof can be matched with a pharmaceutically acceptable carrier and prepared into a tablet, a capsule, a granule, powder, a plaster, an ointment, an aerosol, a suspension, a syrup, an oral liquid, and an injection, and can also beprepared into special dosage forms such as a liposome, microspheres, nanoparticles and an emulsion for cavity administration, external use, oral administration and injection. The individual administration or the combined treatment can be performed, the administration dosage of the Cucurbitacins is calculated according to the total Cucurbitacins, the dosage for healthy adults is between 0.1 and 5mg / d, the best dosage is between 0.3 and 3mg / d, and the administration is performed for 1 to 4 times.
Owner:SHENYANG PHARMA UNIVERSITY +1
Method for extracting cucurbitacin B
The invention relates to a method for extracting cucurbitacin B. The method comprises the following steps of: crushing a raw material of muskmelon pedicel, and wetting the crushed muskmelon pedicel with acidic water; adding a biological enzyme for enzymolysis for 2-4 days at 30-40 DEG C; extracting zymolytic raw materials 2-3 times with 80-95% ethanol; enabling the extracting solution to flow by a short active carbon alumina column and then concentrating until the ethanol concentration is 30-50 percent; standing and crystallizing; carrying out the cold dissolution treatment with chloroform for secondary crystallization; and dissolving under the refluxing of 90-99% ethanol, decoloring with active carbon, removing impurities, recrystallizing, and the like. The method adopted for producing the cucurbitacin B has the advantages of high product yield, low cost and simple process and is easy to operate. The invention is suitable for industrial production.
Owner:NANJING ZELANG AGRI DEV
A kind of active extract of traditional Chinese medicine with alcohol-abstaining effect, its preparation method and application
The invention discloses a traditional Chinese medicine active extract with temperance function, and a preparation method and application thereof. The main active components in the traditional Chinese medicine active extract with temperance function are cucurbitacin compounds, especially cucurbitacin B and cucurbitacin D. The invention also discloses a preparation method of the active extract, andapplication of the active extract in preparing medicines for treating alcoholic psychosis or medicines with temperance function. The active extract can be added by conventional traditional Chinese medicine preparation methods to prepare any clinical preparation after adding various auxiliary materials and carriers required by preparation of different preparation formulations. The active extract disclosed by the invention is a low-toxicity traditional Chinese medicine extract which can be used for effectively treating alcohol dependence and preparing medicines with abstinence function.
Owner:HARBIN MEDICAL UNIVERSITY
Novel application of cucurbitacin B
InactiveCN108785315APrevent proliferationSmall toxicityOrganic active ingredientsAntineoplastic agentsSide effectLymphatic Spread
The invention relates to novel application of cucurbitacin B. Particularly, studies find that the cucurbitacin B can upregulate expression of an LATS1 gene and inhibit expression of a YAP gene and downstream related genes thereof in a colon cancer cell line. Moreover, the cucurbitacin B has the effect of inhibiting proliferation, invasion and metastasis of a human colon cancer SW620 cell line andan HT29 cell line, and can promote apoptosis thereof. The invention finds that the cucurbitacin B can be used as an activator for regulating a Hippo-YAP signaling pathway, is a novel promising effective anticancer medicine, can be used as an active component in preparation of medicines for treating cancers such as human colon cancer, and is conducive to improving the targeting ability of medicinalcancer treatment and reducing toxic and side effects of the medicines.
Owner:HUBEI UNIVERSITY OF MEDICINE
Culture medium applicable to dental pulp stem cell in vitro culture and preparation method thereof
InactiveCN106754678AImprove securityClear ingredientsCulture processSkeletal/connective tissue cellsCuticleTaurine
The invention belongs to the technical field of cell culture, and concretely relates to a culture medium applicable to dental pulp stem cell in vitro culture and a preparation method thereof. The culture medium applicable to dental pulp stem cell in vitro culture provided by the invention comprises a basal culture medium and an additive added in the basal culture medium, wherein the additive is prepared from the following components with final concentration: catalase with the final concentration of 3 to 5 mg / L, coenzyme Q10 with the final concentration of 0.2 to 0.4mu M, linolenic acid with the final concentration of 7 to 9mu M, platelet-derived growth factor with the final concentration of 1 to 3mu g / L, cucurbitacin B with the final concentration of 0.2 to 0.6mg / L, lipoic acid with the final concentration of 0.12 to 0.15mg / L, folic acid with the final concentration of 12 to 15mu M, carboxymethyl chitosan with the final concentration of 0.5 to 1g / L, epidermal growth factor with the final concentration of 8 to 10mu g / L, taurine with the final concentration of 7 to 10mg / L, and attachin with the final concentration of 22 to 30mu g / L. The culture medium provided by the invention is high in safety, lower in price, and beneficial for remarkably improving the proliferation speed of dental pulp stem cells.
Owner:叶宗耀
Application of cucurbitacin B and analogs thereof in preparation of drugs for treating endometrial cancer
ActiveCN103599110APrevent proliferationTo achieve the purpose of individualized treatmentOrganic active ingredientsAntineoplastic agentsIndividualized treatmentTherapeutic intent
The invention discloses an application of cucurbitacin B and analogs thereof in the preparation of drugs for treating endometrial cancer, wherein the analogs are generated by changing the groups in the R1, R2, R3, R4, R5, X, Y, a, and b positions in the cucurbitacin B molecule, and the drugs can be used to carry out an individualized treatment for endometrial cancer patients, wherein the endometrial cancer can be idiopathic or metastatic. Cucurbitacin B and analogs thereof can be any pharmaceutically acceptable cucurbitacin B and analogs thereof, the cucurbitacin B and analogs thereof have one or more components which have the function of inhibiting epidermal growth factor receptor (EGFR), the cucurbitacin B and analogs thereof can be individually used to cure cancer or can be used with other treatments or drugs, such as radiotherapy, chemotherapy, surgical therapy, other growth factor inhibitors and sex hormone inhibitors, and any drugs or methods for treating cancer. Through inhibiting the epidermal growth factor receptor (EGFR), the cucurbitacin B and analogs thereof inhibit the tumor cell proliferation so as to achieve the goal of individualized treatment, and the cucurbitacin B and analogs thereof can be individually used to treat cancer or used with other drugs or treatments for cancer treatment.
Owner:国药集团工业有限公司
Method for refining cucurbitacin raw material and preparation thereof
InactiveCN101134768AFast dissolutionLow toxicityOrganic active ingredientsDigestive systemWhite blood cellKetone
The present invention belongs to the field of medicine technology, and provides cucurbitacin refining process and preparation. The cucurbitacin refining process includes the following steps: 1. dissolving marketed cucurbitacin in C1-C4 alcohol-water dissolved ketone to obtain solution A containing cucurbitacin in 0.1-10 g each 100ml; 2. adding active carbon in0.01-10 g for each 100 ml, stirring for 1-60 min and filtering out carbon to obtain solution B; 3. adding water into solution B to reach alcohol / water volume ratio of 1 to 1-10, and stirring until the solution becomes turbid; 4. letting stand for over night; and 5. filtering, collecting precipitate and drying. The refining process can lower the toxicity of cucurbitacin product, has no altering on cucurbitacin B content and is suitable for industrial production. The cucurbitacin product may be prepared into different preparations for treating tumors, increasing peripheral blood leukocytes and treating hepatitis.
Owner:SHENYANG PHARMA UNIVERSITY
Cucurbitacin B nanometer liposome and preparation thereof
InactiveCN106137966AProlong the action timeReach the lesionOrganic active ingredientsPharmaceutical non-active ingredientsClearance ratePolyethylene glycol
The present invention relates to a cucurbitacin B liposome drug and preparation thereof. The invention provides a cucurbitacin B nanometer liposome drug and a preparation method thereof. According to the present invention, a passive drug delivery way is used, and a substance polyethylene glycol containing polyhydroxy groups is linked to the phospholipid phosphoric acid group to modify so as to prepare the long-circulating nanometer liposome, wherein the structural modification effect is to protect the liposome from being identified and uptaken by opsonin in blood so as to reduce the liposome clearance rate and prolong the residence time in the blood, such that the action time of the drug is prolonged, the liposome can effectively reach the lesion, and the selectivity on the targeted tissue can be improved; the preparation prepared by the preparation method has characteristics of good physical stability, good chemical stability, long residence time in the body, small distribution volume in the body, and high blood drug concentration in the body; the drug of the present invention can be used for treatment of various types and various stages of liver cancers; and the cucurbitacin B liposome drug has characteristics of scientific formula, convenient use, good stability and low toxicity, and the preparation method is suitable for large-scale production.
Owner:TIANJIN INSTITUTE OF PHARMA RESEARCH
Application of cucurbitacin B in preparation of ferroptosis inducer and anti-nasopharyngeal carcinoma drug
InactiveCN111658655AEffective against nasopharyngeal carcinomaNo side effectsOrganic active ingredientsRespiratory disorderParanasal Sinus CarcinomaSide effect
The invention discloses an application of cucurbitacin B in preparation of a ferroptosis inducer and an anti-nasopharyngeal carcinoma drug. The research shows that cucurbitacin B can induce ferroptosis for the first time; death of nasopharyngeal carcinoma cells is regulated and controlled in a novel cell death promoting mode; and further research finds that cucurbitacin B can promote accumulationof iron ions, reduce the content of glutathione in the cells and down-regulate expression of GPX4 in nasopharyngeal carcinoma cells CNE1, so that lipid peroxide is increased, and iron death of the cells is induced. In in-vitro and in-vivo studies, cucurbitacin B induces the CNE1 cell cycle to be blocked in the G2 / M period and inhibits cell migration and invasion. In addition, cucurbitacin B can significantly inhibit growth of mouse nasopharyngeal carcinoma tumors, and has no obvious toxic or side effect. The invention provides a new choice, namely a ferroptosis inducer, for a medicine for treating nasopharyngeal carcinoma; and meanwhile, a natural novel medicine source, namely cucurbitacin B, is provided for a ferroptosis inducer and treatment of nasopharyngeal carcinoma. The cucurbitacinB is efficient and safe and is free of toxic and side effects.
Owner:THE SECOND AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIV
Traditional Chinese medicine active extract with temperance function, and preparation method and application thereof
The invention discloses a traditional Chinese medicine active extract with temperance function, and a preparation method and application thereof. The main active components in the traditional Chinese medicine active extract with temperance function are cucurbitacin compounds, especially cucurbitacin B and cucurbitacin D. The invention also discloses a preparation method of the active extract, andapplication of the active extract in preparing medicines for treating alcoholic psychosis or medicines with temperance function. The active extract can be added by conventional traditional Chinese medicine preparation methods to prepare any clinical preparation after adding various auxiliary materials and carriers required by preparation of different preparation formulations. The active extract disclosed by the invention is a low-toxicity traditional Chinese medicine extract which can be used for effectively treating alcohol dependence and preparing medicines with abstinence function.
Owner:HARBIN MEDICAL UNIVERSITY
Streptomycete for producing glycosidase and application of streptomycete in preparing cucurbitacin B by virtue of biotransformation
ActiveCN103614322AEasy to useSimple nutritional requirementsBacteriaHydrolasesDisaccharidaseCucurbitacin B
The invention provides streptomycete (Streptomyces sp.) RW-2 used as a glycosidase producing bacterium and application of the streptomycete in preparing cucurbitacin B during biotransformation of cucurbitacin B-2-O glucoside. A bacterial strain is preserved in China Center for Type Culture Collection, the address of the China Center for Type Culture Collection is Wuhan University in Wuhan, China, the postcode is 430072, the preservation number is CCTCC NO:M2013330, and the preservation date is July 17th, 2013. The streptomycete has the beneficial effects that (1) the streptomycete is a common bacterium in the fermentation industry and is safe to use without toxicity and harms; (2) the nutritional requirements of the streptomycete RW-2 are simple, the growth speed of the streptomycete RW-2 is rapid, and the streptomycete RW-2 is easily cultivated; (3) the glycosidase prepared by the streptomycete RW-2 is extracellular enzyme, thallus is removed by separating the extracellular enzyme to obtain crude enzyme, or the crude enzyme can be used as a biotransformation system after being diluted; (4) after biotransformation treatment on total cucurbitacin extracted from muskmelon pedicel, the cucurbitacin B-2-O glucoside can be almost entirely transformed into the cucurbitacin B, and the content of the cucurbitacin B can be increased by 1-2.7 times.
Owner:ZHEJIANG UNIV OF TECH
Extraction technology for cucurbitacin D
The invention discloses an extraction technology for cucurbitacin D. The extraction technology comprises the following steps that 1) muskmelon pedicels are fed into a pulverizer to be pulverized so asto obtain pulverized muskmelon pedicels; 2) ethanol reflux extraction is carried out two times on the pulverized muskmelon pedicles so as to obtain an extracting solution; 3) the extracting solutionis concentrated and separated so as to obtain an ethyl acetate layer; and 4), then the ethyl acetate layer is concentrated to be dry, then 10% of pyridine and ethanol are added, refluxing is carried out for 2.5-3.5 h, and separating is carried out so as to obtain the cucurbitacin D. According to the extraction technology, 10% of pyridine and ethanol are adopted as weak base, a large amount of cucurbitacin B in the muskmelon pedicels is converted into the cucurbitacin D, separation and extraction are carried out, so that the extraction rate of the cucurbitacin D is greatly increased, in addition, the technology is simple, and the cost is low.
Owner:湖州展舒生物科技有限公司
Cucumber exosome-like vesicles containing cucurbitacin B and capable of being used as anti-cancer drugs
ActiveCN112472731AGuaranteed stabilityInhibitory activityOrganic active ingredientsAntineoplastic agentsCancer cellTumor therapy
Owner:FUJIAN MEDICAL UNIV
A method of preparing cucurbitacin B
ActiveCN103992366ALow impurity contentDoes not damage the structureSteroidsBulk chemical productionCucurbitacin BNatural product
The invention discloses a method of preparing a natural product cucurbitacin B. According to the method, a supercritical fluid extraction method is adopted to extract a total cucurbitacin extract product from plant, then a silica gel column separation and purification manner is adopted to obtain the cucurbitacin B, and the purity of the cucurbitacin B is higher than 90%. Compared with the prior art, the method for preparing the cucurbitacin B has advantages of short time, high efficiency, small solvent using amount, low environment pollution, and suitability for large-scale production and operation.
Owner:TIANJIN INSTITUTE OF PHARMA RESEARCH
Cucurbitacin B and oxidation-responsive antitumor prodrug co-loaded bionic nanoparticle
InactiveCN111001006AOrganic active ingredientsPharmaceutical non-active ingredientsDiseaseTumor targeting
The invention belongs to the technical field of medicines, and relates to an exosome membrane-coated cucurbitacin B and oxidation-responsive antitumor prodrug co-loaded bionic nanoparticle, and an application thereof in the preparation of drugs for treating tumor metastasis diseases. The nanoparticle can ablate primary tumors and target circulating tumor cells so as to inhibit tumor metastasis. The exosome membrane-coated co-loaded bionic nanoparticle comprises 1-2 wt% of cucurbitacin B, 6-8 wt% of an oxidation-responsive antitumor prodrug, 60-70 wt% of a nano-carrier material, and the balanceof an exosome membrane, and the weight ratio of the cucurbitacin B to the oxidation-responsive antitumor prodrug is 1:4 to 1:8. The exosome membrane-coated cucurbitacin B and oxidation-responsive antitumor prodrug co-loaded bionic nanoparticle has an obvious effect of treating tumor metastasis, especially lung or liver metastasis of breast cancer, and can be used for preparing antitumor drugs.
Owner:SHENYANG PHARMA UNIVERSITY
HPLC (High Performance Liquid Chromatography) method for utilizing chiral column to separate, identify and prepare monomer matter from cucurbitacin mixture
The invention discloses an HPLC (High Performance Liquid Chromatography) method for utilizing a chiral column to separate, identify and prepare a monomer matter from a cucurbitacin mixture. The process conditions of the HPLC method are as follows: the chiral column using an amylose derivative as a solid phase is taken as a chromatographic column; more than two mixtures of isopropanol, alcohol, methyl alcohol, acetonitrile, normal hexane, isohexane, n-pentane, trifluoroacetic acid and glacial acetic acid are taken as mobile phases; and a detection wavelength is 220nm-270nm. The HPLC method provided by the invention is characterized by simple operation, high accuracy and strong specificity. The HPLC method can be used for excellently separating matters, such as cucurbitacin B, iso-cucurbitacin B, dihydro cucurbitacin B, cucurbitacin E, and the like, from the cucurbitacin mixture, can be used for preparing various cucurbitacin monomers from the cucurbitacin mixture and also can be used for accurately measuring contents of cucurbitacin raw materials and various cucurbitacins in a prepared product.
Owner:SHENYANG PHARMA UNIVERSITY
Application of cucurbitacine B and derivatives thereof in preparation of anti-tumor drug-resistant drugs
PendingCN114732820APromote proliferationPromote apoptosisOrganic active ingredientsAntineoplastic agentsCucurbitacin BApoptosis
The invention discloses application of cucurbitacin B and a derivative thereof in preparation of an anti-tumor drug-resistant drug. It is found that the cucurbitacin B inhibits proliferation of an ovarian cancer cis-platinum drug-resistant cell strain, and the IC50 values of the cucurbitacin B to C13 * and A2780DDP cells are 64.28 + / -14.54 nM and 29.20 + / -2.26 nM respectively; the apoptosis of C13 * cells is promoted, and invasion and migration of the C13 * cells are inhibited; and PI3K / Akt signal channels in C13 * and A2780DDP cells are inhibited. Therefore, the cucurbitacine B is applied to preparation of anti-tumor drug-resistant drugs. The cucurbitacine B has a good development prospect.
Owner:FOSHAN MATERNAL & CHILD HEALTH CARE HOSPITAL
A cucumber exosome-like vesicle containing cucurbitacin b as an anticancer drug
ActiveCN112472731BSimple and fast operationIncrease productionOrganic active ingredientsAntineoplastic agentsCancer cellTumor therapy
The invention discloses a cucumber exosome-like vesicle containing cucurbitacin B and can be used as an anticancer drug. Cucurbitacin B can be used to inhibit the proliferation of various cancer cells, but its extraction method is complicated and time-consuming. The method of isolating cucumber exosome-like vesicles to obtain cucurbitacin B has the advantages of simple and rapid operation, and the lipid bilayer of exosome-like vesicles, as the natural protective film of cucurbitacin B, can be used for a long time. maintain its stability. Moreover, the presence of the lipid bilayer also increased the uptake rate of cucurbitacin B by cells to a certain extent through the principle of similar compatibility. When acting on adenocarcinoma human alveolar basal epithelial cells (A549 cells), the maximum cell activity inhibition rate of cucumber exosome-like vesicles is twice that of cucurbitacin B standard, and the dosage is lower, which can reduce the toxicity to normal cells It has good anticancer potential and industrialization prospects, and is of great significance in clinical tumor treatment applications.
Owner:FUJIAN MEDICAL UNIV
A method for isolating cucurbitacin b from melon vines by catalytic reaction
The invention discloses a method for separating cucurbitacin B from muskmelon vines by virtue of catalytic reaction. The method comprises the following steps: an extraction process, namely taking 1 part of the muskmelon vines, soaking by using ethanol, performing reflux extraction, and filtering and concentrating an extracting solution to obtain an extract; the catalytic reaction, namely adding concentrated hydrochloric acid into the extract, then adding ferric trichloride hexahydrate, stirring and reacting, cooling to the room temperature, filtering, performing water rinsing, and drying; a refining process, namely stirring and dissolving a crude product by using ethyl acetate, then adding activated carbon, decoloring, concentrating to a small volume, and standing overnight to perform crystallization; a recrystallization process, namely dissolving a like fine product by using ethanol, filtering and concentrating to a small volume while hot, standing overnight to perform crystallization, and filtering; and putting the fine product in a vacuum drying box, and drying for 8 hours to obtain a cucurbitacin B fine product. The method disclosed by the invention is wide in raw material source and low in production cost, and can be used for reducing the damages of an acid environment to cucurbitacin B; the production rate reaches more than 60%, the purity is more than 99.0%, and the wastewater BOD (biochemical oxygen demand) is less than 100; the method is suitable for the industrial production of recycling water, and can be widely applied to plant extraction industries.
Owner:西安天丰生物科技股份有限公司
Application of cucurbitacin b and its analogues in the preparation of medicines for treating endometrial cancer
ActiveCN103599110BPrevent proliferationTo achieve the purpose of individualized treatmentOrganic active ingredientsSexual disorderIndividualized treatmentTherapeutic intent
The invention discloses an application of cucurbitacin B and analogs thereof in the preparation of drugs for treating endometrial cancer, wherein the analogs are generated by changing the groups in the R1, R2, R3, R4, R5, X, Y, a, and b positions in the cucurbitacin B molecule, and the drugs can be used to carry out an individualized treatment for endometrial cancer patients, wherein the endometrial cancer can be idiopathic or metastatic. Cucurbitacin B and analogs thereof can be any pharmaceutically acceptable cucurbitacin B and analogs thereof, the cucurbitacin B and analogs thereof have one or more components which have the function of inhibiting epidermal growth factor receptor (EGFR), the cucurbitacin B and analogs thereof can be individually used to cure cancer or can be used with other treatments or drugs, such as radiotherapy, chemotherapy, surgical therapy, other growth factor inhibitors and sex hormone inhibitors, and any drugs or methods for treating cancer. Through inhibiting the epidermal growth factor receptor (EGFR), the cucurbitacin B and analogs thereof inhibit the tumor cell proliferation so as to achieve the goal of individualized treatment, and the cucurbitacin B and analogs thereof can be individually used to treat cancer or used with other drugs or treatments for cancer treatment.
Owner:国药集团工业有限公司
Eight diasteromers of vittatalactone and methods of making, and methods of attracting acalymma vittatum
Disclosed are methods for preparing a mixture of eight diasteromers of vittatalactoneAlso disclosed are mixtures of eight diasteromers of vittatalactone produced by the methods described herein. In addition there are described compositions comprising a mixture of eight diasteromers of vittatalactone and optionally (2E,6Z)-nona-2,6-dienaland optionally cucurbitacin B or cucurbitacin B, and optionally a carrier. Furthermore, there are describe methods of attracting Acalymma vittatum to an object or area, involving treating said object or area with a Acalymma vittatum attracting composition containing a Acalymma vittatum attracting effective amount of the compositions described herein.
Owner:US SEC AGRI +1
A method for preparing cucurbitacin b
The invention discloses a method of preparing a natural product cucurbitacin B. According to the method, a supercritical fluid extraction method is adopted to extract a total cucurbitacin extract product from plant, then a silica gel column separation and purification manner is adopted to obtain the cucurbitacin B, and the purity of the cucurbitacin B is higher than 90%. Compared with the prior art, the method for preparing the cucurbitacin B has advantages of short time, high efficiency, small solvent using amount, low environment pollution, and suitability for large-scale production and operation.
Owner:TIANJIN INSTITUTE OF PHARMA RESEARCH
Beta-glucosidase gene, coding enzyme, engineering bacterium and application thereof
The invention discloses a beta-glucosidase gene, a coding enzyme, an engineering bacterium and application thereof in preparation of cucurbitacin B by biotransformation of cucurbitacin B glucoside. The nucleotide sequence of the gene is shown as SEQ ID No. 1. The engineering bacterium containing the recombinant beta-glucosidase gene is subjected to induced expression culture, thalli are collected and subjected to ultrasonication, the obtained cell lysis solution is used as a catalyst, a muskmelon pedicel ethanol extract methanol solution is used as a substrate, a transformation reaction system is formed in a PBS buffer solution, and the cucurbitacin B is prepared through transformation. The beta-glucosidase gene and the engineering bacterium are derived from a streptomyces RW-2 strain, the cell lysis solution can be used as a biocatalyst, the cucurbitacin B glucoside is transformed into the cucurbitacin B, the concentration of the substrate of the reaction system is increased by 3.89 times, and the transformation rate of the cucurbitacin B glucoside into the cucurbitacin B reaches 90.2%.
Owner:ZHEJIANG UNIV OF TECH +1
Streptomyces producing glucosidase and its application in biotransformation to prepare cucurbitacin b
ActiveCN103614322BEasy to useSimple nutritional requirementsBacteriaHydrolasesCucurbitacin BDisaccharidase
The invention provides streptomycete (Streptomyces sp.) RW-2 used as a glycosidase producing bacterium and application of the streptomycete in preparing cucurbitacin B during biotransformation of cucurbitacin B-2-O glucoside. A bacterial strain is preserved in China Center for Type Culture Collection, the address of the China Center for Type Culture Collection is Wuhan University in Wuhan, China, the postcode is 430072, the preservation number is CCTCC NO:M2013330, and the preservation date is July 17th, 2013. The streptomycete has the beneficial effects that (1) the streptomycete is a common bacterium in the fermentation industry and is safe to use without toxicity and harms; (2) the nutritional requirements of the streptomycete RW-2 are simple, the growth speed of the streptomycete RW-2 is rapid, and the streptomycete RW-2 is easily cultivated; (3) the glycosidase prepared by the streptomycete RW-2 is extracellular enzyme, thallus is removed by separating the extracellular enzyme to obtain crude enzyme, or the crude enzyme can be used as a biotransformation system after being diluted; (4) after biotransformation treatment on total cucurbitacin extracted from muskmelon pedicel, the cucurbitacin B-2-O glucoside can be almost entirely transformed into the cucurbitacin B, and the content of the cucurbitacin B can be increased by 1-2.7 times.
Owner:ZHEJIANG UNIV OF TECH
Novel medical use of cucurbitacin
Owner:SHENYANG PHARMA UNIVERSITY +1
Human dental pulp stem cell culture medium and preparation method thereof
InactiveCN107828723APromote proliferationAct as a stabilizerCulture processSkeletal/connective tissue cellsAdditive ingredientTaurine
The invention discloses a human dental pulp stem cell culture medium and a preparation method thereof. The culture medium is prepared from a basic culture medium and additives, wherein the basic culture medium is an alpha-MEM culture medium, and the additives are prepared from human AB serum with the volume percentage as 6 to 12%, 5 to 10mg / L of taurine, 0.1 to 0.2mg / L lipoic acid, 2 to 5mg / L of grape seed extract, 0.6 to 1.5g / L of carboxymethyl chitosan, 0.3 to 0.8mg / l of cucurbitacin B, 1 to 4mu g / L of platelet derived growth factor, 1 to 4mu g / L of epidermal growth factor, 0.6 to 1.8mg / L ofdiosgenin and 50 to 65mu M of choline chloride. The human dental pulp stem cell culture medium disclosed by the invention is prepared from specific ingredients, all the ingredients has an synergisticeffect, a dental pulp cell amplification speed can be remarkably improved, multidirectional differentiation capacity of the dental pulp stem cells is not affected, meanwhile human immune rejection isavoided, and reliable seed cells can be provided for clinical tooth repair and regeneration.
Owner:重庆斯德姆生物技术有限公司
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com